ONCO.ST
Oncopeptides AB (publ) [ONCO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ONCO.ST Stock Summary
Top 10 Correlated Stocks
ONCO.ST
In the News
ONCO.ST Financial details
Company Rating
-
Market Cap
427.94M
Income
-259M
Revenue
30.44M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-2.58
Forward P/E
-
PEG
0.3
P/S
22.38
P/B
5.01
P/C
-
P/FCF
-2.26
Quick Ratio
5.59
Current Ratio
6.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.87
EPS next Y
-
EPS next Q
-
EPS this Y
-78.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-89.19%
EPS Q/Q
-27.42%
-
-
-
-
SMA20
-
SMA50
150%
SMA100
150%
Inst Own
-
Inst Trans
-
ROA
-88%
ROE
-124%
ROC
-1.08%
Gross Margin
106%
Oper. Margin
-897%
Profit Margin
-851%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.0-11.87
52W High
-56.5%
52W Low
+19.63%
RSI
52
Rel Volume
6.68
Avg Volume
435.2K
Volume
2.91M
Perf Week
4.25%
Perf Month
-10.23%
Perf Quarter
219%
Perf Half Y
204.78%
-
-
-
-
Beta
-0.605
-
-
Volatility
0.24%, 0.41%
Prev Close
-6.18%
Price
4.785
Change
-6.54%
Company Profile
- Volume Average 435.2K
- Market Capitalization 427.94M
- Employee 57
- CEO Ms. Sofia Heigis M.Sc.
- Headquarters Stockholm,SE
- IPO Date 2017-02-22
-
Website
https://www.oncopeptides.com/sv 
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
